What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Read original at benzingaStocks · News reference
AbCellera’s ABCL635 Meets Primary Endpoints In Phase 2 Vasomotor Symptom Study
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global impression of
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 11:44 AM
- Checked
- Aug 10, 2026, 11:44 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Read original at benzinga8-K filing — AbCellera Biologics Inc. (ABCL)
Filed: 2026-08-13 AccNo: 0001193125-26-349353 Size: 616 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarAbCellera Prices Oversubscribed $200.0M Offering Of 17,435,897 Common Shares At $9.75 Per Share
Read original at benzinga